Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection
Open Access
- 1 January 2014
- journal article
- review article
- Published by SAGE Publications in Clinical Medicine Insights: Women's Health
- Vol. 7, 1-8
- https://doi.org/10.4137/cmwh.s10353
Abstract
Human Immunodeficiency Virus (HIV) is a retrovirus that can result in rare opportunistic infections occurring in humans. The onset of these infections is known as Acquired Immune Deficiency Syndrome (AIDS). Sexual transmission is responsible for the majority of infections 1, resulting in transmission of HIV due to infected semen or vaginal and cervical secretions containing infected lymphocytes. HIV microbicides are formulations of chemical or biological agents that can be applied to the vagina or rectum with the intention of reducing the acquisition of HIV. Tenofovir is an NRTI that is phosphorylated by adenylate kinase to tenofovir diphosphate, which in turn competes with deoxyadeosine 5′-triphosphate for incorporation into newly synthesized HIV DNA. Once incorporated, tenofovir diphosphate results in chain termination, thus inhibiting viral replication. Tenofovir has been formulated into a range of vaginal formulations, such as rings, tablets gels and films. It has been shown to safe and effective in numerous animal models, while demonstrating safety and acceptability in numerous human trials. The most encouraging results came from the CAPRISA 004 clinical trial which demonstrated that a 1% Tenofovir vaginal gel reduced HIV infection by approximately 39%.Keywords
This publication has 62 references indexed in Scilit:
- Preformulation and Development of a Once-Daily Sustained-Release Tenofovir Vaginal Tablet Tablet Containing A Single ExcipientJournal of Pharmaceutical Sciences, 2013
- MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other CompartmentsPLOS ONE, 2013
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Couples' acceptability of the SILCS diaphragm for microbicide deliveryContraception, 2012
- Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 ReplicationCell Host & Microbe, 2011
- Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202The Journal of Infectious Diseases, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 MicrobicidePLOS ONE, 2010
- Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with EmtricitabineJournal of Virology, 2009
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialPublished by American Medical Association (AMA) ,2004